Safety and pharmacokinetics of multiple dosing with inhalable apomorphine (AZ-009), and its efficacy in a randomized crossover study in Parkinson's disease patients

A Randomized Trial Assessing the Safety, Pharmacokinetics, and Efficacy During Morning Off of AZ ‐009

(2022) Eva Thijssen et al.   MOVEMENT DISORDERS

Pharmacokinetics and Comparative Bioavailability of Apomorphine Sublingual Film and Subcutaneous Apomorphine Formulations in Patients with Parkinson’s Disease and “OFF” Episodes: Results of a Randomized, Three-Way Crossover, Open-Label Study

(2021) Felix Agbo et al.   Neurology and Therapy

Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson's Disease

(2020) Beth E. Safirstein et al.   CLINICAL THERAPEUTICS

LC-MS/MS simultaneous quantification of apomorphine and its major metabolites in human plasma: Application to clinical comparative bioavailability evaluation for the apomorphine sublingual film and a subcutaneous product

(2020) Yu-Luan Chen et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial

(2019) Peter A LeWitt et al.   LANCET NEUROLOGY

Apomorphine for Parkinson’s Disease: Efficacy and Safety of Current and New Formulations

(2019) Federico Carbone et al.   CNS DRUGS

Learning from Parkinson’s patients: Usability of the Cyclops dry powder inhaler

(2019) M. Luinstra et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study

(2019) C Warren Olanow et al.   LANCET NEUROLOGY

International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease

(2018) Susan H. Fox et al.   MOVEMENT DISORDERS

Motor and non-motor wearing-off and its impact in the quality of life of patients with Parkinson's disease

(2018) Mayela Rodríguez-Violante et al.   ARQUIVOS DE NEURO-PSIQUIATRIA

A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease

(2016) Peter A. LeWitt et al.   MOVEMENT DISORDERS

Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinsons disease

(2016) M. M. Lipp et al.   Science Translational Medicine

A Randomized Controlled Trial of Subcutaneous Apomorphine for Parkinson Disease

(2015) Masahiro Nomoto et al.   CLINICAL NEUROPHARMACOLOGY

Can Patients with Parkinson’s Disease Use Dry Powder Inhalers during Off Periods?

(2015) M. Luinstra et al.   PLoS One

Inhaled dry powder apomorphine (VR040) for ‘off ’ periods in Parkinson's disease: an in-clinic double-blind dose ranging study

(2013) K. A. Grosset et al.   ACTA NEUROLOGICA SCANDINAVICA

Early DEtection of wEaring off in Parkinson disease: The DEEP study

(2013) F. Stocchi et al.   PARKINSONISM & RELATED DISORDERS

Efficacy and Safety of Loxapine for Inhalation in the Treatment of Agitation in Patients With Schizophrenia

(2011) Michael H. Allen et al.   JOURNAL OF CLINICAL PSYCHIATRY

Open-Label Study Assessment of Safety and Adverse Effects of Subcutaneous Apomorphine Injections in Treating "Off" Episodes in Advanced Parkinson Disease

(2008) Peter A. LeWitt et al.   CLINICAL NEUROPHARMACOLOGY

Intermittent Subcutaneous Apomorphine Therapy for ???Off??? Episodes in Parkinson??s Disease

(2008) Richard M Trosch et al.   CNS DRUGS

Recurrent atrial fibrillation after subcutaneous apomorphine

(2007) Gianluca Ardolino et al.   PARKINSONISM & RELATED DISORDERS